Affinivax, founded with a core mission to innovate in vaccine technology, is a clinical-stage biotechnology company focused on developing both preventive and therapeutic vaccines. Their vision is to provide broader protection against infectious and immune-mediated diseases. Utilizing their proprietary Multiple Antigen Presenting System (MAPS) platform, Affinivax aims to create vaccines that offer enhanced efficacy and coverage compared to traditional methods.

Notable affiliated people include scientific advisors and leaders in immunology and vaccine development. The company has garnered significant investment from healthcare-focused venture capital firms. Key achievements include advancing multiple vaccine candidates into clinical trials, demonstrating promising results in terms of safety and immunogenicity. Affinivax's impact lies in its potential to revolutionize the vaccine landscape, offering solutions that could significantly reduce the burden of infectious diseases globally.